Fernando Arias-Mendoza1, Franklyn Howe2, Marion Stubbs3, Seung-Cheol Lee4, Geoffrey S. Payne5, Kristen Zakian6, Hamed Mojahed1, Harish Poptani4, Mary McLean3, Amita Shukla-Dave6, Nicholas R. Maisey5, Owen A. O'Connor7,8, Ruth Pettengell9, Steven J. Schuster4, David Cunningham10, John R. Griffiths3, Jerry D. Glickson4, Martin O. Leach5, Jason A. Koutcher6, Arend Heerschap11, Truman R. Brown1
1Radiology, Columbia University, New York, NY, United States; 2Radiology, St. George's Hospital, London, United Kingdom; 3Radiology, Cambridge University, Cambridge, United Kingdom; 4Radiology, University of Pennsylvania, Philadelphia, PA, United States; 5Radiology, Institute of Cancer Research, London, United Kingdom; 6Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States; 7Medical Oncology, Columbia University, New York, NY, United States; 8Medical Oncology, New York University, New York, NY, United States; 9Medical Oncology, St. George's Hospital, London, United Kingdom; 10Medical Oncology, Institute of Cancer Research, London, United Kingdom; 11Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
In vivo localized, 31P and 1H MRS was acquired in tumors of non-Hodgkins lymphoma patients before treatment, and the phosphoethanolamine plus phosphocholine-to-nucleoside triphosphate and total choline-to-water ratios determined in the 31P and 1H tumor spectra respectively. In these preliminary data, the pretreatment ratios showed a linear correlation (y=0.16x 0.77, r2=0.7, p<0.005). This correlation and the increased sensitivity of 1H observations in comparison to those of 31P suggests that the prediction of therapeutic outcome by MR technology can be improved by the addition of 1H spectroscopy to the in vivo MR observations of NHL patients.